Testing Effect of InterventionHOTNCT06634342
One-step HCV RNA Testing Among SSP Participants (HOT Study)
A study testing HCV RNA Rapid testing in people with Testing Effect of Intervention, run by University of Washington at 1 site in United States.
Trial summary
The HOT (HCV One-step Test) Study is an observational prospective study to evaluate the use of a recently FDA-approved point-of-care RNA test for hepatitis C virus (HCV) in a sample of clients of a syringe services program (SSP). The investigators aim to answer the following questions: 1. Read more about this study
- Who is it for?
- Ages 22 years and olderHealthy volunteers can take part
- Conditions the study is for
- Testing Effect of Intervention
- What is being tested?
- HCV RNA Rapid testing
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Feb 2025to 30 Apr 2026
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Minimum age of 22
Who cannot join
- Already knows they are infected with hepatitis C virus.
- Past participation in this study.
Trial locations and contacts
1 site in 1 country.
United States1 site
Public Health-Seattle & King County
Seattle, Washington, 98104
About this study
Official title: Clinical Utility and Feasibility of a One-step HCV Testing Algorithm for Clients of a U.S. Syringe Services Program
The HOT (HCV One-step Test) Study is an observational prospective study to evaluate the use of a recently FDA-approved point-of-care RNA test for hepatitis C virus (HCV) in a sample of clients of a syringe services program (SSP). The investigators aim to answer the following questions:
- How will point-of-care HCV RNA testing with the Xpert HCV test, provided at an SSP, affect how people who use drugs receive their results, get linked to HCV care services, and initiate and complete HCV treatment?
2: What are the most effective ways to implement point of care HCV RNA testing in syringe services programs?
Read the detailed description
This study will be conducted in partnership with the Public Health - Seattle \& King County SSP in Seattle WA. The PHSKC SSP will be provided with a Cepheid Xpert HCV RNA machine and testing cartridges. Staff will be trained by Cepheid staff on the one-step HCV RNA testing protocol, including collecting blood from participants, using the test machine, interpreting results, and returning results to participants.
HCV testing and linkage to care activities will be monitored for six months as part of this study. Once all training and protocol development is complete, the PHSKC SSP will make the one-step HCV testing algorithm available to their clients and invite them to participate. SSP staff will conduct the one-step HCV testing and linkage algorithm according to the project protocol.
Clients who choose to be tested will participate in an informed consent process for study procedures. Participants who complete the HCV test and receive their results will receive a $15 incentive. All quantitative data related to the study will be entered directly into REDCap data collection tools. SSP staff who conduct testing will record a participant's HCV test result, whether/when they received their result, and whether/when they received a referral to HCV care. Participants will need to provide identifying information (e.g., name and birthdate) and sign a release of information form to facilitate longitudinal data collection on linkage to care and treatment initiation. SSP staff will use this information to follow up with providers to indicate whether/when participants attended an HCV care visit, whether/when participants began HCV treatment, and if they achieved cure (i.e., sustained viral response at 4 weeks). No other information will be requested or recorded from health care providers.
Investigators will ask the PHSKC SSP to gather data on prior HCV testing and linkage efforts for the 6 months prior to the implementation of the one-step algorithm (standard of care). This will include any data that are available related to volume of HCV screening and RNA testing, participant receipt of results, and linkage to care efforts.
During the six months of the testing project, investigators will also conduct qualitative data collection. First, UW staff will conduct 12 in-depth interviews with participants who were involved in the testing component of the study. These interviews will be conducted with participants who received negative HCV RNA results, both those who were and were not linked to care, and those who started HCV treatment. The goal of these interviews will be to understand the participants' previous testing experiences and interest in HCV care, present testing experiences and interest in care, and overall impressions of the one-step testing algorithm. Staff will use purposive sampling to recruit participants and conduct private interviews using a semi-structured interview guide. Participants who complete these interviews will receive a $40 incentive.
Second, UW staff will conduct in-depth interviews with all staff at the PHSKC SSP who were involved with the HCV testing study to understand the experiences of staff who conducted the one-step testing algorithm compared to previous testing algorithms (e.g., HCV rapid screening and/or laboratory-based HCV RNA testing). Specific questions will assess facilitators and barriers to providing one-step HCV testing in SSPs, as well as recommendations for implementing similar protocols in other SSPs.
- Conditions
- Testing Effect of Intervention
- Being tested
- HCV RNA Rapid testing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HCV RNA Rapid testingDiagnostic test
Participants will receive point-of-care hepatitis C RNA testing using the GeneXpert IV Xpress System technology.
| Study group | Role | What they receive |
|---|---|---|
| Participants of a syringe services program | Experimental | Participants of the syringe services program who will be offered point-of-care hepatitis C RNA testing will be adults 22 or older who do not already know they have HCV infection. Receives: Diagnostic Test: HCV RNA Rapid testing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Receipt of HCV RNA Test Results
Percentage of individuals who complete a HCV RNA test and who also receive their test results.
Measured: 6 months
Linkage to HCV Care
Percentage of individuals who test positive for HCV who are connected with HCV treatment services
Measured: 6 months
Cure Rate
Percentage of individuals who test positive for HCV who are cured of HCV.
Measured: 6 months
Secondary outcomes (2)
Testing Results
Percentage of participants who receive an HCV RNA test who test positive for HCV
Measured: 6 months
Testing Willingness
Percentage of participants offered the HCV RNA test who agree to be tested
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2024
- Study start5 Feb 2025
- Primary completion31 May 2025
- Study completion30 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Testing Effect of InterventionStudies of the same condition, open and under way.
- More trials run by University of WashingtonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Washington
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sara Glick, University of Washington
- Investigators
- Sara Glick, PhD, MPH, Principal investigator, University of Washington
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06634342
- Sponsor's protocol ID
- STUDY00021203
- Acronym
- HOT
- Status last verified
- May 2026
- First submitted
- 7 Oct 2024
- Last updated
- 24 Jun 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Glick SN, Kingston S, Wilson-Weiberg K, Casey A, Schwarcz L, Vivas Jimenez G, Parsigian T, Tinsley J, Golden MR, Balkus JE. Successful Implementation of Hepatitis C Virus Point-of-Care Testing in a Syringe Services Program. Subst Use Addctn J. 2026 Jul 12:29767342261462112. doi: 10.1177/29767342261462112. Online ahead of print.
PubMed 42437493
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Utility and Feasibility of a One-step HCV Testing Algorithm for Clients of a U.S. Syringe Services Program
- ClinicalTrials.gov ID
- NCT06634342
- Acronym / sponsor ID
- HOT / STUDY00021203
- Conditions
- Testing Effect of Intervention
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- University of WashingtonUniversity, hospital or other
- Study start
- 5 Feb 2025 (actual)
- Primary completion
- 31 May 2025 (actual)
- Study completion
- 30 Apr 2026 (actual)
- First posted
- 9 Oct 2024 (actual)
- Results
- Posted 24 Jun 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The HOT (HCV One-step Test) Study is an observational prospective study to evaluate the use of a recently FDA-approved point-of-care RNA test for hepatitis C virus (HCV) in a sample of clients of a syringe services program (SSP). The investigators aim to answer the following questions:
- How will point-of-care HCV RNA testing with the Xpert HCV test, provided at an SSP, affect how people who use drugs receive their results, get linked to HCV care services, and initiate and complete HCV treatment?
2: What are the most effective ways to implement point of care HCV RNA testing in syringe services programs?
Detailed description
This study will be conducted in partnership with the Public Health - Seattle \& King County SSP in Seattle WA. The PHSKC SSP will be provided with a Cepheid Xpert HCV RNA machine and testing cartridges. Staff will be trained by Cepheid staff on the one-step HCV RNA testing protocol, including collecting blood from participants, using the test machine, interpreting results, and returning results to participants.
HCV testing and linkage to care activities will be monitored for six months as part of this study. Once all training and protocol development is complete, the PHSKC SSP will make the one-step HCV testing algorithm available to their clients and invite them to participate. SSP staff will conduct the one-step HCV testing and linkage algorithm according to the project protocol.
Clients who choose to be tested will participate in an informed consent process for study procedures. Participants who complete the HCV test and receive their results will receive a $15 incentive. All quantitative data related to the study will be entered directly into REDCap data collection tools. SSP staff who conduct testing will record a participant's HCV test result, whether/when they received their result, and whether/when they received a referral to HCV care. Participants will need to provide identifying information (e.g., name and birthdate) and sign a release of information form to facilitate longitudinal data collection on linkage to care and treatment initiation. SSP staff will use this information to follow up with providers to indicate whether/when participants attended an HCV care visit, whether/when participants began HCV treatment, and if they achieved cure (i.e., sustained viral response at 4 weeks). No other information will be requested or recorded from health care providers.
Investigators will ask the PHSKC SSP to gather data on prior HCV testing and linkage efforts for the 6 months prior to the implementation of the one-step algorithm (standard of care). This will include any data that are available related to volume of HCV screening and RNA testing, participant receipt of results, and linkage to care efforts.
During the six months of the testing project, investigators will also conduct qualitative data collection. First, UW staff will conduct 12 in-depth interviews with participants who were involved in the testing component of the study. These interviews will be conducted with participants who received negative HCV RNA results, both those who were and were not linked to care, and those who started HCV treatment. The goal of these interviews will be to understand the participants' previous testing experiences and interest in HCV care, present testing experiences and interest in care, and overall impressions of the one-step testing algorithm. Staff will use purposive sampling to recruit participants and conduct private interviews using a semi-structured interview guide. Participants who complete these interviews will receive a $40 incentive.
Second, UW staff will conduct in-depth interviews with all staff at the PHSKC SSP who were involved with the HCV testing study to understand the experiences of staff who conducted the one-step testing algorithm compared to previous testing algorithms (e.g., HCV rapid screening and/or laboratory-based HCV RNA testing). Specific questions will assess facilitators and barriers to providing one-step HCV testing in SSPs, as well as recommendations for implementing similar protocols in other SSPs.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants of a syringe services program | Experimental | Diagnostic Test: HCV RNA Rapid testingParticipants of the syringe services program who will be offered point-of-care hepatitis C RNA testing will be adults 22 or older who do not already know they have HCV infection. |
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Minimum age of 22
Key exclusion criteria (2 listed)
- Already knows they are infected with hepatitis C virus.
- Past participation in this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HCV RNA Rapid testingParticipants will receive point-of-care hepatitis C RNA testing using the GeneXpert IV Xpress System technology. | Diagnostic test | Participants of a syringe services program |
Primary outcome
Receipt of HCV RNA Test Results
Time frame: 6 months
Percentage of individuals who complete a HCV RNA test and who also receive their test results.
Linkage to HCV Care
Time frame: 6 months
Percentage of individuals who test positive for HCV who are connected with HCV treatment services
Cure Rate
Time frame: 6 months
Percentage of individuals who test positive for HCV who are cured of HCV.
2 secondary outcomes
Testing Results
Time frame: 6 months
Testing Willingness
Time frame: 6 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42437493Glick SN, Kingston S, Wilson-Weiberg K, Casey A, Schwarcz L, Vivas Jimenez G, Parsigian T, Tinsley J, Golden MR, Balkus JE. Successful Implementation of Hepatitis C Virus Point-of-Care Testing in a Syringe Services Program. Subst Use Addctn J. 2026 Jul 12:29767342261462112. doi: 10.1177/29767342261462112. Online ahead of print.
- Individual participant dataSharing planned: No
Related trials for Testing Effect of Intervention
Enrolling by invitation
ProFoUND PCC= A Program For a Userbased Nursing Development in Person-Centered Care, is a Project That Aims to Develop, Test and Evaluate Effects of a Co-created Intervention to Increase Person-centred Care in Residential Care Settings for Older People.
To Develop, Test, Implement and Evaluate a Model for Person-centred Care for Older People at Two Academic Residential Care Facilities
Recruiting
Internet-Based EMDR Flash Intervention for Test Anxiety in University Students
Test Anxiety
Recruiting
Effect of Video -Based vs Standard ınformation on Maternal Anxiety and Procedure Decision in Pregnant Woman Offered Amniocentesis or Cvs
Maternal Anxiety, Prenatal Diagnosis
Recruiting
Mindful Moms, Mindful Meals (MMMM) Study
Nutrition in Early Infancy, Nutrition Habits
Not yet recruiting
Effect of Web-Based Education on Attitudes and Beliefs About HPV Testing
Cervical Cancer, HPV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sara Glick, PhD, MPH principal investigator
University of Washington
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing HCV RNA Rapid testing in people with Testing Effect of Intervention, run by University of Washington at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 24 Jun 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Receipt of HCV RNA Test Results (time frame: 6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06634342, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2026.